Trimelamol

Trimelamol (CB10-375; NSC283162) is a highly efficient acid-catalyzed DNA interstrand crosslinker with low neurotoxicity due to its limited BBB penetration. Trimelamol exhibits anti-tumor activity and overcomes platinum resistance. Trimelamol is investigated for lung and ovarian cancer research[1][2][3][4][5].

Product Specifications

CAS Number

[64124-21-6]

Product Name Alternative

CB 10-375; NSC 283162

UNSPSC

12352005

Target

DNA Alkylator/Crosslinker

Related Pathways

Cell Cycle/DNA Damage

Field of Research

Cancer

Smiles

OCN(C1=NC(N(C)CO)=NC(N(C)CO)=N1)C

Molecular Formula

C9H18N6O3

Molecular Weight

258.28

References & Citations

[1]I R Judson, et al. Phase I trial and pharmacokinetics of trimelamol (N2, N4, N6-trihydroxymethyl-N2, N4, N6-trimethylmelamine) . Cancer Res. 1989 Oct 1;49 (19) :5475-9.|[2]I R Judson, et al. Low central nervous system penetration of N2, N4, N6, -trihydroxymethyl-N2, N4, N6, -trimethylmelamine (Trimelamol) : a cytotoxic s-triazine with reduced neurotoxicity. Br J Cancer. 1986 May;53 (5) :601-6.|[3]C Jackson, et al. N2, N4, N6-tri (hydroxymethyl) -N2, N4, N6-trimethylmelamine (trimelamol) is an efficient DNA cross-linking agent in vitro. Biochem Pharmacol. 1991 Nov 6;42 (11) :2091-7.|[4]H M Coley, et al. Pre-clinical development of the anti-tumour agent CB 7646, bis N- (hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol. Int J Cancer. 1996 Nov 4;68 (3) :356-63.|[5]Y Yamada, et al. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice. Oncol Rep. 1996 Jul;3 (4) :613-7.